Published in Inflamm Bowel Dis on January 01, 2004
Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol (2010) 1.87
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One (2012) 1.74
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis (2007) 1.08
Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A (2008) 1.07
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol (2009) 1.06
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model. J Neuroinflammation (2005) 0.92
Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol (2007) 0.91
Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2005) 0.91
Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol (2014) 0.90
Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol (2009) 0.89
Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease. Gut (2006) 0.88
Neurological disorders and inflammatory bowel diseases. World J Gastroenterol (2014) 0.86
Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol (2008) 0.82
Optic neuritis after infliximab therapy. Rheumatol Int (2011) 0.81
A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect (2012) 0.81
Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease. J Crohns Colitis (2016) 0.80
Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature. Rheumatol Int (2011) 0.80
Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag (2007) 0.78
Demyelinizing Neurological Disease after Treatment with Tumor Necrosis Factor-α Antagonists. Case Rep Ophthalmol (2016) 0.76
A practical approach to monitoring patients on biological agents for the treatment of psoriasis. J Clin Aesthet Dermatol (2010) 0.75
Central nervous system demyelination associated with etanercept in a 51 years old woman. Libyan J Med (2007) 0.75
Neurologic Manifestations of Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2014) 0.75
A practical approach to screening psoriasis patients for therapy with biologic agents. J Clin Aesthet Dermatol (2008) 0.75
Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Aliment Pharmacol Ther (2014) 0.75
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain (2010) 4.77
Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50
Crohn's disease. Lancet (2012) 4.42
Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Ulcerative colitis. Lancet (2012) 3.38
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol (2008) 3.30
Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol (2012) 2.88
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol (2009) 2.80
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology (2007) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol (2006) 2.67
Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol (2008) 2.58
Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55
Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol (2008) 2.41
Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 2.37
Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2006) 2.34
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15
Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 2.12
A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis (2014) 2.09
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology (2013) 2.04
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut (2013) 2.03
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol (2006) 2.03
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol (2002) 1.89
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol (2009) 1.86
Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis (2007) 1.85
Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol (2010) 1.82
An approach to the diagnosis of acute transverse myelitis. Semin Neurol (2008) 1.80
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol (2010) 1.74
Acute disseminated encephalomyelitis: current understanding and controversies. Semin Neurol (2008) 1.72
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol (2007) 1.72
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol (2004) 1.69
Assessment of small bowel Crohn disease: noninvasive peroral CT enterography compared with other imaging methods and endoscopy--feasibility study. Radiology (2003) 1.63
Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol (2009) 1.61
Crohn Disease: mural attenuation and thickness at contrast-enhanced CT Enterography--correlation with endoscopic and histologic findings of inflammation. Radiology (2006) 1.60
Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol (2003) 1.60
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol (2005) 1.59
Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg (2010) 1.54
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol (2010) 1.54
Microscopic colitis: a review. Am J Gastroenterol (2002) 1.53
A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology (2008) 1.53
Advances in the treatment of Crohn's disease. Gastroenterology (2004) 1.51
Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology (2006) 1.51
Solitary sclerosis: progressive myelopathy from solitary demyelinating lesion. Neurology (2012) 1.49
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol (2011) 1.49
Crohn's disease complicated by strictures: a systematic review. Gut (2013) 1.46
Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther (2012) 1.45
Fistulas to the urinary system in Crohn's disease: clinical features and outcomes. Am J Gastroenterol (2002) 1.45
The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler (2011) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42